PR Newswire - Telix Announces Positive rPFS Data from ProstACT S...
TLX591 is an investigational anti-PSMA[1] radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing r...
Read More

ภาษาไทย
English